The best medical device stocks depend on your portfolio and investment goals — while volatility can be ideal for day traders, long-term investors will want to look to stocks with steadier gains over time.
The top health product stocks included on this page all trade on the S&P 500, have an analyst recommendation of "Buy" or better and are sorted by year-to-date performance.
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Abbott Laboratories stock opened the day at $127.68 after a previous close of $127.21. The latest price was $125.60 (25-minute delay). Abbott Laboratories is listed on the NYSE, has a trailing 12-month revenue of around USD41.9 billion and employs 114,000 staff.
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients.
ABIOMED stock opened the day at $0.00 after a previous close of $0.00. The latest price was $0.00 (25-minute delay). ABIOMED is listed on the NASDAQ, has a trailing 12-month revenue of around USD$1.1 billion and employs 2,003 staff.
Align Technology, Inc. designs, manufactures, and markets Invisalign clear aligners, Vivera retainers, and iTero intraoral scanners and services in the United States, Switzerland, and internationally. The Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package to treat adults and teens from mild to severe malocclusion and features, and orthodontic needs of teenage or younger patients; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years with a mixture of primary/baby and permanent teeth.
Align Technology stock opened the day at $170.92 after a previous close of $170.37. The latest price was $170.00 (25-minute delay). Align Technology is listed on the NASDAQ, has a trailing 12-month revenue of around USD$4 billion and employs 20,945 staff.
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands. It also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve.
Edwards Lifesciences stock opened the day at $71.46 after a previous close of $71.35. The latest price was $71.24 (25-minute delay). Edwards Lifesciences is listed on the NYSE, has a trailing 12-month revenue of around USD$5.4 billion and employs 15,800 staff.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, proprietary programming software, radiofrequency ablation, indirect decompression systems, and intraosseous nerve ablation and deep brain stimulation systems.
Boston Scientific stock opened the day at $102.86 after a previous close of $102.67. The latest price was $103.08 (25-minute delay). Boston Scientific is listed on the NYSE, has a trailing 12-month revenue of around USD$16.7 billion and employs 53,000 staff.
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products.
Medtronic stock opened the day at $90.28 after a previous close of $90.13. The latest price was $88.59 (25-minute delay). Medtronic is listed on the NYSE, has a trailing 12-month revenue of around USD$33.2 billion and employs 95,000 staff.
Penumbra, Inc. , together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
Penumbra stock opened the day at $285.02 after a previous close of $280.38. The latest price was $286.23 (25-minute delay). Penumbra is listed on the NYSE, has a trailing 12-month revenue of around USD$1.2 billion and employs 4,500 staff.
Inogen, Inc. , a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Inogen stock opened the day at $7.48 after a previous close of $7.37. The latest price was $7.37 (25-minute delay). Inogen is listed on the NASDAQ, has a trailing 12-month revenue of around USD$335.7 million and employs 766 staff.
SmileDirectClub, Inc. , an oral care company, offers clear aligner therapy treatment. The company manages the end-to-end process, which include marketing, aligner manufacturing, fulfillment, treatment by a customer's dentist or orthodontist, and facilitating remote clinical monitoring through a network of orthodontists and general dentists through its proprietary teledentistry platform, SmileCheck in the United States, Puerto Rico, Canada, Australia, the United Kingdom, New Zealand, Ireland, Hong Kong, Germany, Singapore, France, Spain, and Austria.
SmileDirectClub stock opened the day at $0.00 after a previous close of $0.00. The latest price was $0.00 (25-minute delay). SmileDirectClub is listed on the NASDAQ, has a trailing 12-month revenue of around USD$414.9 million and employs 2,700 staff.
Check out Finder's picks for the best brokerage accounts
Compare top brokerage accounts and apps to help you maximize your investment.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Learn how and where to buy Fannie Mae (FNMA) stock, view trends and see what may be ahead for share holders.
See how and where to buy Freddie Mac (FMCC) stock, view past price performance and learn what’s ahead for shareholders.
Explore the best bonuses for opening a new brokerage account.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out these Fundrise competitors.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
Is the Stock Advisor program worth it? Pros and cons to consider before you sign up.
Compare pros, cons, research tools and reviews for these two trading platforms.
SoFi Invest is a no-fee commissions platform with both active and automated investment accounts.
A deep dive into the highlights and limitations of Robinhood.